Last Updated: 03/08/2023
Evaluation of the affinity antibodies induced by Plasmodium vivax multi-antigen based formulations in mice
Objectives
To evaluate the magnitude of the antibody response, as well their affinity in C57BL/6 mice sera immunized with a new recombinant chimeric protein involving the two antigens (yPvCSP-MSP119), expressed in Pichia pastoris yeasts, in the presence of the adjuvant Poly(I:C).
Malaria is considered a serious problem of public health, which can cause severe forms and lead to death, mainly among children under 5 years of age living in Sub-Saharan Africa. In America, an infection caused by Plasmodium vivax represents 74.1% of cases, currently, according to the Pan American Health Organization. Due to the increase in drug and insecticide resistance, the development of a vaccine formulation against this parasite is of great importance to its control and eradication. Due to the complexity of the parasite’s life cycle and invasion strategies, vaccine formulations containing more than one antigen from different stages of P. vivax have been explored. Previous studies from our group described the importance of proteins such as MSP119 and CSP as immunodominant antigens.
May 2022 — Feb 2023
